Australia unites taking small steps to make a big difference for melanoma research
23 March 2016
Melanoma March events have been an outstanding success across the country, with more than 6,000 dedicated supporters turning out for marches across 23 locations over the last month. Well over $600,000 has been raised, with two weeks of the campaign still remaining.
The Melbourne event, held early in March, attracted around 1,500 supporters, while 800 turned out for the Brisbane march last weekend. Over 700 supporters, including NSW Premier Mike Baird and rugby legend John Eales, braved the ominous clouds at Manly, while the inaugural march in Penrith attracted 500 people.
A team of volunteers and MIA staff ensured the events ran smoothly, arriving on site well before dawn to help set up, managing registrations, selling merchandise and staying back to pack up after events. MIA’s clinicians also attended events sharing their clinical insights and experiences with local crowds.
MIA’s CEO Carole Renouf who walked at the Wollongong and Manly marches said: “It takes an incredible amount of work behind the scenes to ensure events go to plan. We couldn’t do it without our incredible volunteers including staff members who took time out of their weekends to help. It was a real team effort and it was fantastic to see so many staff involved.
“I’d also like to thank our patients who bravely shared their stories with media and spoke at events. I was moved and inspired to hear about their experiences. They are the reason we do what we do.”
The final Melanoma March will be in Darwin on Sunday 10 April.
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.
Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.
Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research.
We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role.
Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category.
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.
We have a winner!